Edesa Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
Date of Report: March 16, 2021
Company: Edesa Biotech, Inc. (EDSA)
Event: Entry into a Material Definitive Agreement (Item 1.01)
On March 16, 2021, Edesa Biotech, Inc., through its subsidiary Edesa Biotech Research, Inc., entered into an exclusive license agreement with Dr. Saul Yedgar. This agreement expands Edesa's rights to a pharmaceutical product that serves as the basis for its EB01 and EB02 drug candidates.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain periodic financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Agreement Financial Terms:
- Milestone Payments: Edesa is committed to pay up to approximately $69.2 million upon meeting certain milestones.
- License Fees: A fixed license fee is required for each full calendar year if an Investigational New Drug (IND) application is not filed within a specified period.
- Royalties: Edesa must pay royalties based on net sales in countries where it directly commercializes the product and a percentage of sublicensing revenue in other countries.
Material Changes
Expansion of Rights: Previously, Edesa held exclusive rights to the pharmaceutical product only for topical dermatology and certain gastrointestinal indications via a sublicense from Yissum Research Development Company. Under this new agreement, Edesa now holds exclusive global rights to the product for all fields of use in humans and animals, excluding topical dermal and anorectal applications.
Intellectual Property Ownership: While Dr. Yedgar remains the exclusive owner of the licensed technology, Edesa will be the exclusive owner of all new patents and intellectual property created by or on behalf of Edesa after the agreement date, including improvements to the licensed technology.
Outlook, Risks, and Obligations
Development Obligations: Edesa is exclusively responsible for the development and commercialization of the product at its own expense. The company must use commercially reasonable efforts to adhere to a development plan established by the parties.
Term: The agreement expires on a country-by-country basis on the later of the expiry of the last valid licensed patent or 15 years after the first commercial sale in that country.
Risks and Contingencies:
- Termination: Dr. Yedgar may terminate the agreement if Edesa defaults, subject to a cure period. Edesa may terminate if it determines the product is no longer commercially viable.
- Indemnification: Edesa has undertaken to indemnify Dr. Yedgar against liabilities arising from the use, development, manufacture, marketing, sale, or sublicensing of the product.
- Patent Maintenance: Edesa is responsible for preparing, filing, prosecuting, and maintaining patents in Dr. Yedgar's name.
Investor Verification Checklist
- Verify the specific timeline for the required filing of the Investigational New Drug (IND) application to avoid fixed license fees.
- Review the detailed milestone definitions in the attached Exhibit 10.1 to understand the triggers for the $69.2 million in potential payments.
- Assess the impact of the expanded global rights on the company's current cash burn rate and capital requirements.
- Confirm the status of the existing sublicense agreement with Yissum Research Development Company regarding the excluded topical dermal and anorectal applications.